Want to see AU:OSX full AI Analyst Report?
OSX Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.05
Previous CloseN/A
Volume70.28K
Average Volume (3M)2.16M
Market Cap
AU$3.12M
Enterprise ValueAU$825.77K
Total Cash (Recent Filing)AU$626.97K
Total Debt (Recent Filing)AU$198.80K
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding693,592,900
10 Day Avg. Volume675,672
30 Day Avg. Volume2,156,422
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.70
Price to Sales (P/S)0.40
P/FCF Ratio-0.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthMulti-year revenue expansion demonstrates durable commercial traction for Osteopore’s bioresorbable implants, signaling growing adoption by hospitals and distributors. Persistent top-line growth supports scale benefits, broader market penetration and a foundation for future operating leverage as fixed costs are absorbed.
High Gross MarginA ~53% gross margin indicates strong product economics and potential pricing power for the 3D‑printed implants. Sustained mid‑to‑high gross margins give room to invest in R&D and commercial expansion while making reaching profitability easier once operating expenses stabilize or grow more slowly than revenue.
Lower LeverageMaterial reduction in debt meaningfully lowers refinancing and interest burden risk, improving financial flexibility. With smaller short‑term liabilities, the company has more runway to execute commercial plans or negotiate partnerships without acute near‑term default or covenant pressure.
Bears Say
Persistent Net LossesContinued multi‑million net losses reflect an ongoing inability to cover operating costs from revenue. This structural loss profile requires external financing or dilution, constrains reinvestment into sales and R&D, and delays a durable path to profitability absent material margin or cost improvements.
Negative Cash FlowPersistent negative operating and free cash flow means the business is not self‑funding and depends on external capital. FCF closely tracks net losses (~1x), indicating limited non‑cash accounting relief; ongoing cash burn raises funding risk and may force dilution or suboptimal financing choices.
Negative Shareholders' EquityNegative equity is a structural balance‑sheet weakness that reduces financial flexibility and can hinder access to new debt or commercial terms. It raises solvency concerns with counterparties and increases dependence on future capital raises to sustain growth and meet obligations.
Osteopore Ltd. News
OSX FAQ
What was Osteopore Ltd.’s price range in the past 12 months?
Osteopore Ltd. lowest share price was <AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Osteopore Ltd.’s market cap?
Osteopore Ltd.’s market cap is AU$3.12M.
When is Osteopore Ltd.’s upcoming earnings report date?
Osteopore Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 14 days.
How were Osteopore Ltd.’s earnings last quarter?
Osteopore Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Osteopore Ltd. overvalued?
According to Wall Street analysts Osteopore Ltd.’s price is currently Overvalued.
Does Osteopore Ltd. pay dividends?
Osteopore Ltd. does not currently pay dividends.
What is Osteopore Ltd.’s EPS estimate?
Osteopore Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Osteopore Ltd. have?
Osteopore Ltd. has 693,592,900 shares outstanding.
What happened to Osteopore Ltd.’s price movement after its last earnings report?
Osteopore Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Osteopore Ltd.?
Currently, no hedge funds are holding shares in AU:OSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Osteopore Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.50%
Trailing 12-Months
Company Description
Osteopore Ltd.
Established in Singapore in 2003, Osteopore Limited focuses on engineering, manufacturing, and globally commercializing bioresorbable polymer implants. These advanced devices are utilized in neurosurgical, orthopedic, and maxillofacial operations throughout Singapore, Australia, and other international regions. The company's core innovation involves employing 3D printing with bioresorbable materials to create custom, micro-structured scaffolds specifically designed to foster bone regeneration. Its product portfolio includes Osteoplug, a resorbable implant for sealing trephination burr holes during neurosurgery, and Osteomesh, another resorbable implant used in craniofacial surgery to mend various fractures, including orbital floor injuries, and to fill surgical voids. Additionally, Osteopore has forged a collaborative partnership with Livingstone Health Holding Limited to jointly pioneer new products and applications for bone and tissue regeneration.